Trial Profile
Study of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients treated with radium-223 (Ra-223) therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 30 Aug 2018 New trial record